Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 7Fallopian Tube Neoplasms 3Endometrial Neoplasms 3Uterine Cervical Neoplasms 2Thyroid Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Ovarian Epithelial 2Breast Neoplasms 2Uterine Neoplasms 1Urinary Bladder Neoplasms 1Thoracic Neoplasms 1Testicular Neoplasms 1Testicular Germ Cell Tumor 1Teratoma 1Stomach Neoplasms 1Seminoma 1Sarcoma, Synovial 1Sarcoma, Kaposi 1Sarcoma, Endometrial Stromal 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Rhabdomyosarcoma 1Rectal Neoplasms 1Prostatic Neoplasms 1Pelvic Neoplasms 1Pancreatic Neoplasms 1Osteosarcoma 1Neurofibrosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Nervous System Neoplasms 1

Interventions

Paclitaxel 2Nivolumab 2Gemcitabine 2Bevacizumab 2rucaparib 1pembrolizumab 1liposomal doxorubicin 1dostarlimab 1Taxes 1Sunitinib 1Ipilimumab 1Immunoglobulin G 1Doxorubicin 1Docetaxel 1Disulfides 1Celecoxib 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma, Clear Cell × Sunitinib × Gynecologic × Clear all
NCT01824615 2018-07-18

Sunitinib® in Patients With Recurrent Ovarian Clear Cell Carcinoma

Cathay General Hospital

Phase 2 Completed
30 enrolled
Gynecologic

Ovarian Neoplasms, Adenocarcinoma, Clear Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡